publication date: Oct. 19, 2018
Conversation with The Cancer Letter Sharpless: “I am now looking at the entire portfolio—focusing on areas where NCI is an essential player”
A year after starting his job as NCI director, Ned Sharpless is reviewing the entire spectrum of NCI research in an effort to focus on areas where the institute plays a key role.
NCI is able to make these decisions in fiscal 2019 more efficiently, because for the first time in two decades, the spending bills have cleared Congress on time (The Cancer Letter, Sept. 28).
Managing expectations is one of the problems Sharpless faces at a time of increasing funding.
“Because the majority of NCI grants are for multi-year research efforts, our grant portfolio includes multi-year commitments,” Sharpless said to The Cancer Letter, responding to a question about his plans for stamping his vision on the institute.
Sharpless said that even though NCI has received a $400 million bolus of Moonshot funding, which will drop to $195 million in fiscal 2020, the institute may end up reserving some for the new funds for a smooth downward transition. “The funds provided … Continue reading Sharpless: “I am now looking at the entire portfolio—focusing on areas where NCI is an essential player”
To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us
and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.